bluebird bio
JOBS
IN THE PRESS
bluebird bio, Inc. announced that new data from the completed Phase 1/2 Northstar study will be presented in an oral session at the 23rd Annual Congress of the European Hematology Association.
bluebird bio, Inc. announced that members of the management team will present at the following upcoming investor conferences in June:
Cerebral adrenoleukodystrophy is a rare, serious and life-threatening hereditary neurological disorder.
bluebird bio, Inc. reported financial results and business highlights for the first quarter ended March 31, 2018.
bluebird bio, Inc. announced interim data published in the New England Journal of Medicine (NEJM) from two separate two-year clinical studies investigating the potential for LentiGlobin™ gene therapy to eliminate or reduce chronic blood transfusions in patients with transfusion-dependent β-thalassemia (TDT).
bluebird and Celgene will share 50% of U.S. costs and profits
bluebird bio, Inc. today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2017.
In this role, Alison will be responsible for shaping and delivering an integrated global commercial strategy to make bluebird’s gene therapies broadly accessible to patients.
bluebird bio today announced that it has issued an additional 277,109 shares of common stock at the public offering price of $185 per share, for total gross proceeds of approximately $51.3 million.
Goldman Sachs 10th Annual Healthcare CEOs Unscripted, Thursday, January 4, at 3:15 p.m. ET at the InterContinental, Boston, Massachusetts.